4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer

Estrogen receptor (ER) positive tumors represent the majority of breast malignancies, and are effectively treated with hormonal therapies, such as tamoxifen. However, in the recurrent disease resistance to tamoxifen therapy is common and a major cause of death. In recent years, in-depth proteome analyses have enabled identification of clinically useful biomarkers, particularly, when heterogeneity in complex tumor tissue was reduced using laser capture microdissection (LCM). In the current study, we performed high resolution proteomic analysis on two cohorts of ER positive breast tumors derived from patients who either manifested good or poor outcome to tamoxifen treatment upon recurrence.

Source: Molecular Oncology - August 6, 2015 Category: Cancer & Oncology Authors: Tommaso De Marchi, Ning Qing Liu, Cristoph Stingl, Mieke A. Timmermans, Marcel Smid, Maxime P. Look, Mila Tjoa, Rene B.H. Braakman, Mark Opdam, Sabine C. Linn, Fred C.G.J. Sweep, Paul N. Span, Mike Kliffen, Theo M. Luider, John A. Foekens, John W.M. Marte Source Type: research